Form 4: Verve Therapeutics Director Burt A. Adelman Reports Stock Option Grant

Director Burt A. Adelman reports the grant of stock options in Verve Therapeutics, Inc.

Summary

• Burt A. Adelman, a director of Verve Therapeutics, Inc., reported a transaction on June 26, 2024.
• Adelman was granted stock options to purchase 136,139 shares of common stock at an exercise price of $5.02 per share.
• The options vest upon the earlier of the one-year anniversary of the grant date or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director.
• The options expire on June 25, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard director compensation practice, indicating a neutral to slightly positive sentiment due to alignment of interests.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

NA

Industry Context

Stock option grants are a common form of compensation for directors of publicly traded companies, aligning their interests with those of shareholders.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.

Key Dates